Meeting
2022 ASCO Genitourinary Cancers Symposium
Evaluation of ctDNA alterations in mCRPC patients with germline pathogenic mutations.
Authors
Malcolm Light
Tulane University, New Orleans, LA
Malcolm Light , Ellen B. Jaeger , Sydney Caputo , William Fleming , Charlotte Manogue , Minqi Huang , Isabelle P. Sussman , Alex Lieberman , Patrick Miller , Pedro C. Barata , Jodi Lyn Layton , Brian E. Lewis , Elisa M. Ledet , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 177)
DOI
10.1200/JCO.2022.40.6_suppl.177
Abstract #
177
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluation of ctDNA in patients with CRPC with pathogenic germline mutations in BRCA2.
First Author: Minqi Huang
Poster
2021 Genitourinary Cancers Symposium
5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.
First Author: Martin Sjöström
Poster
2021 Genitourinary Cancers Symposium
Baseline pathogenic mutations in non-AR/non-TP53 genes and prediction of response to high-dose testosterone.
First Author: Ellen Jaeger
Poster
2019 ASCO Annual Meeting
AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
First Author: Marcus W. Moses